Trade BioXcel Therapeutics, Inc. - BTAI CFD

Add to favourite

0.54

View detailed chart

To be able to trade stocks like this, create an account and apply for a stock listing.

Create Account

Summary
Historical Data

Trading сonditions

Spread

0.05

Long position overnight fee

-0.024151%

Short position overnight fee

0.001929%

Overnight fee time

22:00 (UTC)

Min traded quantity

Currency

USD

Margin

5.00%

Stock exchange

United States of America

Commission on trade

Key Stats

Prev. Close	0.5
Open	0.54
1-Year Change	-87.17%
Day's Range	0.5 - 0.54

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Nov 15, 2024	0.54	0.02	3.85%	0.52	0.55	0.50
Nov 14, 2024	0.50	-0.10	-16.67%	0.60	0.60	0.47
Nov 13, 2024	0.60	-0.05	-7.69%	0.65	0.65	0.57
Nov 12, 2024	0.64	-0.02	-3.03%	0.66	0.68	0.61
Nov 11, 2024	0.69	0.02	2.99%	0.67	0.70	0.64
Nov 8, 2024	0.65	-0.01	-1.52%	0.66	0.66	0.63
Nov 7, 2024	0.64	-0.06	-8.57%	0.70	0.74	0.63
Nov 6, 2024	0.70	0.06	9.37%	0.64	0.72	0.64
Nov 5, 2024	0.66	0.05	8.20%	0.61	0.66	0.61
Nov 4, 2024	0.62	-0.01	-1.59%	0.63	0.63	0.59
Nov 1, 2024	0.62	-0.02	-3.13%	0.64	0.66	0.62
Oct 31, 2024	0.64	-0.05	-7.25%	0.69	0.69	0.62
Oct 30, 2024	0.69	-0.02	-2.82%	0.71	0.80	0.67
Oct 29, 2024	0.68	0.06	9.68%	0.62	0.69	0.62
Oct 28, 2024	0.64	0.05	8.47%	0.59	0.65	0.59
Oct 25, 2024	0.58	0.00	0.00%	0.58	0.63	0.58
Oct 24, 2024	0.57	0.01	1.79%	0.56	0.59	0.55
Oct 23, 2024	0.55	0.00	0.00%	0.55	0.56	0.53
Oct 22, 2024	0.56	0.02	3.70%	0.54	0.57	0.53
Oct 21, 2024	0.53	-0.02	-3.64%	0.55	0.55	0.52

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

1:1
2:1
3:1
5:1
10:1
20:1

Leverage

20:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

BioXcel Therapeutics, Inc. Company profile

About BioXcel Therapeutics Inc

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company. The Company is focused on drug development that utilizes artificial intelligence (AI) approaches to develop therapies in neuroscience and immuno-oncology. The Company's two advanced clinical development programs are BXCL501, an investigational, orally dissolving, sublingual thin film formulation of the adrenergic receptor agonist dexmedetomidine (Dex), for the treatment of agitation resulting from neuropsychiatric disorders, and BXCL701, an investigational orally administered systemic innate immune activator for the treatment of a rare form of prostate cancer and advanced solid tumors that are refractory or treatment-naive to checkpoint inhibitors.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, BioXcel Therapeutics Inc revenues was not reported. Net loss increased 30% to $106.9M. Higher net loss reflects General and administrative increase from $24.3M to $54.2M (expense), Interest income decrease of 72% to $44K (income), Interest expense increase of 48% to $40K (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$3.79 to -$4.05.

Industry:

Bio Therapeutic Drugs

555 Long Wharf Dr
NEW HAVEN
CONNECTICUT 06511-6107
US

News

Shiba Inu coin price prediction 2030: could Shiba Inu coin reach $1? Third party price target

Can Shiba Inu reinvent itself to become a worthy long-term investment?

08:36, 15 November 2024

Trump trades charge as Bitcoin hits $US80,000

Bitcoin hits $80,000 amid expectations of fiscal stimulus, lower regulatory risks, and resilient US economy.

10:48, 13 November 2024

Australian jobs data expected to point to solid labour market conditions

Australian labour market and wage data to reveal job growth resilience, shaping RBA rate cut expectations and impacting AUD amidst global economic shifts.

10:16, 13 November 2024

FOMC cuts interest rates as expected and sticks to its line on future policy

The FOMC cut interest rates by 25 basis points at its November meeting, aligning with expectations. Wall Street hit record highs following the decision, with tech stocks leading the rally. Markets are pricing in a probable December cut amid resilient economic indicators.

13:33, 8 November 2024

FOMC and BOE preview: further rate cuts expected

Both the Federal Reserve and the Bank of England are expected to cut rates further when they meet later this week.

14:14, 5 November 2024

RBA meeting preview: No change to policy expected as inflation fight continues

The Reserve Bank of Australia is expected to keep its cash rate on hold at 4.35% when it announces its policy decision at 2.30PM on the 5th of November, 2024. Despite ongoing evidence of soft demand, upside risks to inflation are likely to remain the central bank’s primary concern.

13:35, 4 November 2024